| Identification | Back Directory | [Name]
1,3-Benzodioxol-5-ol,6-[1-pyrrolidinyl(3,4,5-trimethoxyphenyl)methyl]- | [CAS]
116409-29-1 | [Synonyms]
NSC 370284
1,3-Benzodioxol-5-ol,6-[1-pyrrolidinyl(3,4,5-trimethoxyphenyl)methyl]- | [Molecular Formula]
C21H25NO6 | [MOL File]
116409-29-1.mol | [Molecular Weight]
387.43 |
| Hazard Information | Back Directory | [Uses]
NSC-370284 is a selective inhibitor of ten-eleven translocation 1 (TET1) and 5-hydroxymethylcytosine (5hmC). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5[1]. | [in vivo]
NSC-370284 (2.5 mg/kg; i.p., once daily for 10 days) improves the pathological morphologies in peripheral blood (PB), bone marrow (BM), spleen, and liver tissues in MLL-AF9 acute myeloid leukemia (AML) mice model[1]. | Animal Model: | C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice[1]. | | Dosage: | 2.5?mg/kg. | | Administration: | Intraperitoneal injection, once daily, for 10 days. | | Result: | Significantly inhibited MLL-AF9 induced AML in secondary bone marrow transplantation (BMT) recipient mice. |
| [IC 50]
STAT3; STAT5; TET1 | [References]
[1] Jiang X, et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat Commun. 2017 Dec 13;8(1):2099. DOI:10.1038/s41467-017-02290-w |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|